GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » Sloan Ratio %

Xcorporeal (Xcorporeal) Sloan Ratio % : -250.59% (As of Sep. 2009)


View and export this data going back to . Start your Free Trial

What is Xcorporeal Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Xcorporeal's Sloan Ratio for the quarter that ended in Sep. 2009 was -250.59%.

As of Sep. 2009, Xcorporeal has a Sloan Ratio of -250.59%, indicating earnings are more likely to be made up of accruals.


Xcorporeal Sloan Ratio % Historical Data

The historical data trend for Xcorporeal's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal Sloan Ratio % Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -100,650.00 - -16.15 60.62 -535.23

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -405.60 -535.23 -735.93 -937.88 -250.59

Competitive Comparison of Xcorporeal's Sloan Ratio %

For the Medical Devices subindustry, Xcorporeal's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcorporeal's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xcorporeal's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Xcorporeal's Sloan Ratio % falls into.



Xcorporeal Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Xcorporeal's Sloan Ratio for the fiscal year that ended in Dec. 2008 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2008 )-Cash Flow from Operations (A: Dec. 2008 )
-Cash Flow from Investing (A: Dec. 2008 ))/Total Assets (A: Dec. 2008 )
=(-22.987--12.736
-13.037)/4.351
=-535.23%

Xcorporeal's Sloan Ratio for the quarter that ended in Sep. 2009 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Sep. 2009 )
=(-2.973--5.385
-5.166)/1.099
=-250.59%

Xcorporeal's Net Income for the trailing twelve months (TTM) ended in Sep. 2009 was -0.199 (Dec. 2008 ) + -0.177 (Mar. 2009 ) + -1.056 (Jun. 2009 ) + -1.541 (Sep. 2009 ) = $-2.97 Mil.
Xcorporeal's Cash Flow from Operations for the trailing twelve months (TTM) ended in Sep. 2009 was -2.351 (Dec. 2008 ) + -2.007 (Mar. 2009 ) + -0.852 (Jun. 2009 ) + -0.175 (Sep. 2009 ) = $-5.39 Mil.
Xcorporeal's Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2009 was 2.505 (Dec. 2008 ) + 1.644 (Mar. 2009 ) + 0.899 (Jun. 2009 ) + 0.118 (Sep. 2009 ) = $5.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcorporeal  (GREY:XCRP) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Sep. 2009, Xcorporeal has a Sloan Ratio of -250.59%, indicating earnings are more likely to be made up of accruals.


Xcorporeal Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Xcorporeal's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcorporeal (Xcorporeal) Business Description

Traded in Other Exchanges
N/A
Address
80 Empire Drive, Lake Forest, CA, USA, 92630
Website
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.
Executives
Kelly J. Mccrann director, officer: Chairman and CEO 11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins director C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc 10 percent owner 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer director, 10 percent owner, officer: Executive Chairman 11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf director 981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen director 22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte 10 percent owner C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122

Xcorporeal (Xcorporeal) Headlines